AU637745B2 - Creation of Inventions and Patents with Artificial Intelligence

AU637745B2 – Use of tenidap to inhibit the activity of myeloperoxidase
– Google Patents

AU637745B2 – Use of tenidap to inhibit the activity of myeloperoxidase
– Google Patents
Use of tenidap to inhibit the activity of myeloperoxidase

Download PDF
Info

Publication number
AU637745B2

AU637745B2
AU19574/92A
AU1957492A
AU637745B2
AU 637745 B2
AU637745 B2
AU 637745B2
AU 19574/92 A
AU19574/92 A
AU 19574/92A
AU 1957492 A
AU1957492 A
AU 1957492A
AU 637745 B2
AU637745 B2
AU 637745B2
Authority
AU
Australia
Prior art keywords
tenidap
myeloperoxidase
activity
collagenase
salts
Prior art date
1990-03-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU19574/92A
Other versions

AU1957492A
(en

Inventor
Warren Darrel Blackburn Jr.
Leland David Loose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Inc

Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1990-03-19
Filing date
1992-07-09
Publication date
1993-06-03

1992-07-09
Application filed by Pfizer Inc
filed
Critical
Pfizer Inc

1992-09-10
Publication of AU1957492A
publication
Critical
patent/AU1957492A/en

1993-06-03
Application granted
granted
Critical

1993-06-03
Publication of AU637745B2
publication
Critical
patent/AU637745B2/en

2011-03-18
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/33—Heterocyclic compounds

A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins

A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole

A61K31/404—Indoles, e.g. pindolol

A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P19/00—Drugs for skeletal disorders

A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget’s disease

A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget’s disease for osteoporosis

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P27/00—Drugs for disorders of the senses

A61P27/02—Ophthalmic agents

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P3/00—Drugs for disorders of the metabolism

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P35/00—Antineoplastic agents

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Description

S37745 S F Ref: 214078
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT
ORIGINAL
Name and Address of Applicant: Actual Inventor(s): Address for Service: Invention Title: Pfizer Inc.
235 East 42nd Street New York New York 10017 UNITED STATES OF AMERICA Narren Darrel Blackburn Jr. and Leland David Loose Spruson Ferguson, Patent Attorneys Level 33 St Martins Tower, 31 Market Street Sydney, New South Wales, 2000, Australia Use of Tenidap to Inhibit the Activity of Myeloperoxidase The following statement is a full description of this invention, including the best method of performing it known to me/us:- 5845/5 1 USE OF TENIDAP TO INHIBIT THE ACTIVITY OF
MYELOPEROXIDASE
This invention relates to the use of tenidap and the pharmaceutically- acceptable base salts thereof to inhibit the activity of myeloperoxidase in a mammal. The methods of this invention comprise administering an effective amount of tenidap or salts thereof to such a mammal Tenidap, 5-chloro-2,3-dihydro-2-oxo-3-(2-thienyl-carbonyl)-indole- 1-carboxamide, has the structural formula S0- C1
N
RXJ/0930Z -2- Tenidap and the pharmaceutically-acceptable base salts thereof, among other 3-substituted-2-oxindole-lcarboxamides, are disclosed and claimed in U.S.
4,556,672 which is assigned to the assignee hereof.
That patent discloses that those compounds, in addition to being useful as antiinflammatory and analgesic agents, are inhibitors of both the cyclooxygenase (CO) and lipoxygenase (LO) enzymes. The teachings thereof are incorporated herein by reference.
The use of tenidap and its pharmaceuticallyaccceptable base salts, among certain other 3-substituted-2-oxindole-l-carboxamides, to inhibit interleukin- biosynthesis in a mammal and to treat interleukin-l mediated disorders and dysfunctions is disclosed in U.S. 4,861,794 which is assigned to the assignee hereof.
U.S. 4,853,409′, assigned to the assignee hereof, discloses the’use of tenidap.and its pharmaceuticallyacceptable base salts, among certain other 3-substituted-2-oxindole-l-carboxaides, to suppress T-cell function in a mammal and to treat T-cell mediated autoimmune disorders of the systemic or organ specific type.
An anhydrous, crystalline form of the sodium salt of tenidap is disclosed in European Patent Application 277,738 which has been filed in the name of the assignee hereof.
Collagenase is a protease which is stored within neutrophil specific granules in a latent form. [Hasty, et al., J. Biol. Chem. 261:5645-5650 (1986) and Hasty, et al., J. Biol. Chem. 262:10048-10052 (1987).] Collagenase, in its activated form, mediates a variety of disorders and diseases in a mammal. These disorders and diseases include, but are not limited to, bone resorption disorders such as osteoporosis and metastatic bone cancer, corneal ulceration, periodontal disease, inflammatory joint disease, inflammatory diseases and wounds of the skin and burns. [Harris, et al., NEJM 291:605-609 (1974) and Harris, E.D., et al., NEJM 291:652-660 (1974).] Collagenase can be activated from its latent form by hypochlorous acid.
[Weiss, et al., Science 227:747-749 (1985).] The enzyme myeloperoxidase converts hydrogen peroxide, itself the dismutased product of superoxide radicals, into hyp6chlorous acid. Once activated, collagenase is capable of irreversibly cleaving collagen of types 1, 2 and 3. [Hasty, et al., J. Biol. Chem.
262:10048-10052 (1987).] It has been reported that certain gold compounds can interfere with activated collagenase, but only in the presence of organomercurials. [Mallya, et al., J. Biol. Chem. 264:1594-1601 (1989) and Mallya, S.K. et al., Biochem. Biophys. Res. Comm. 144:101-108 (1987).] Further, penicillamine has been reported to scavenge hypochlorite and inhibit its formation by myeloperoxidase. [Cuperus, et al., Arthritis Rheum. 28:1228-1233 (1985).] However, until the invention herein, there was no 2eport of use or intent to use tenidap or the salts thereof to inhibit the activation of collagenase and to treat collagenase mediated disorders and diseases such -4as bone resorption disorders, corneal ulceration, periodontal disease, inflammatory diseases of the skin and burns with tenidap nor any appreciation of its role in such treatments. Further, there was no report of use or intent to use tenidap or the salts thereof to inhibit the activity of myeloperoxidase with tenidap nor any appreciation of its ability to inhibit myeloperoxidase in a mammal.
It has been found that tenidap and the pharmaceutically-acceptable base salts thereof inhibit the activation of collagenase in a mammal and thus are useful in inhibiting the activation of collagenase per se and in treating collagenase mediated disorders and diseases. Such collagenase mediated disorders and diseases include, but are not limited to, bone resorption disorders, corneal ulceration, periodontal disease, inflammatory diseases and wounds of the skin and burns. Further, it has been found that tenidap and its pharmaceutically-acceptable base salts inhibit the activity of myeloperoxidase in a mammal and are useful in inhibiting myeloperoxldase per se.
According to a broad format therefore, this invention provides a method of inhibiting the activity of myeloperoxidase in a mammal in need thereof which comprises administering to said mammal a myeloperoxidase inhibiting amount of tenidap or a pharmaceutically-acceptable base salt thereof.
The method of using tenidap and its pharmaceutically-acceptable base salts comprises administering to a mammal an effective amount thereof. Administration can comprise any known method for therapeutically providing a compound to a mammal such as by oral or parenteral administration as defined hereinbelow.
RXJ/0930Z Tenidap, which has the chemical structure CloC
-S
I
0 NH 2 its pharmaceutically-acceptable base salts and the preparation thereof are described in U.S. 4,556,672, the teaching of which are incorporated herein by reference. This invention concerns new uses for tenidap and its salts which comprise inhibiting the activation of collagenase in a mammal and inhibiting the activity of myeloperoxidase in a mammal. Also within the’scope of this invention are methods of treating collagenase mediated disorders and diseases in a mammal. Such collagenase mediated disorders and diseases include, but are not limited to, bone resorption disorders such as osteoporosis and metastatic bone cancer, corneal ulceration, periodontal disease, inflammatory diseases and wounds of the skin and burns.
As disclosed in U.S. 4,556,672, tenidap is acidic and forms base salts. All such base salts are within the scope of this invention and can be formed as taught by that patent. Such suitable salts, within the scope of this invention, include both the organic and inorganic types and include, but are not limited to, -6the salts formed with ammonia, organic amines, alkali metal hydroxides, alkali metal carbonates, alkali metal bicarbonates, alkali metal hydrides, alkali metal alkoxides, alkaline earth metal hydroxides, alkaline earth metal carbonates, alkaline earth metal hydrides and alkaline earth metal alkoxides. Representative examples of bases which form such base salts include ammonia, primary amines, such as n-propylamine, n-butylamine, anili’ cyclohexylamine, benzylamine, p-toluidine, ethanolamine and glucamine; secondary amines, such as diethylamine, diethanolamine, N-methylglucamine, N-methylaniline, morpholine, pyrrolidine and piperidine; tertiary amines, such as triethylamine, triethanolamine., N,N-dimethylaniline, N-ethylpiperidine and N-methylmorpholine; hydroxides, such as sodium hydroxide; alkoxides such as sodium ethoxide and potassium methoxide.; hydrides such as calcium hydride and sodium hydride; and carbonates such as potassium carbonate and sodium carbonate, Preferred salts are those of sodium, potassium, ammonium, ethanolamine, diethanolamine and triethanolamine.
Particularly preferred are the sodium salts. An anhydrous crystalline form of such a sodium salt is disclosed in European Patent Application 277,738, filed in the name of the assignee hereof. The teachings thereof which are incorporated herein by reference.
Also within the scope of this invention are the solvates such as the hemihydrates and monohydrates of the compounds hereinabove described.
The methods of this invention comprise administering tenidap and .the pharmaceutically-acceptable -7base salts thereof to a mammal. Such compounds and their salts can be administered to said mammal either alone or, preferably, in combination with pharmaceutically-acceptable carriers or diluents in a pharmaceutical composition, according to standard pharmaceutical practice. Such administration can be oral or parenteral. Parenteral administration as used herein includes, but is not limited to, intravenous, intramuscular, intraperitoneal, subcutaneous, transdurmal and topical including, but not limited to oral lavage and inhalation, administration. While it is generally preferred to administer such compounds and their salts orally, other methods may be preferred depending upon the particular collagenase-mediated disorder or disease being treated.
In general, tenidap and its salts are most desirably administered in doses ranging from about mg up to about 200 mg per day, with a preferred range of about 40 mg to about 120 mg per day, for oral administration and from about 1 mg up to about 200 mg per day for parenteral administration, although variations will still necessarily occur depending upon the weight of the subject being treated. The appropriate dose for inhibiting the activity of myeloperoxidase and/or inhibiting the activation of collagenase in a mammal and for treatment of collagenase mediated disorders and diseases with tenidap and its salts will be readily determined by those skilled in the art of prescribing and/or administering such compounds. Nevertheless, it is still to be appreciated that other variations may also occur in this respect, depending upon the species of mamnmal being treated and its individual response to -8said medicament, as well as on the particular type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful or deleterious side effects to occur, provided that such higher dose levels are first ‘divided into several smaller doses that are to be administered throughout the day.
For purposes of oral administration, tablets containing excipients such as sodium citrate, calcium carbonate and dicalcium phosphate may be employed along with various disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose’, gelatin and acacia; Additionally, lubricating agents such as, but not limited to, magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft elastic and hard-filled gelatin capsules; preferred materials in this connection also include, by way of example and not of limitation, lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the essential active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
-9- Although the generall. preferred mode of administration of tenidap or its pharmaceuticallyacceptable base salts is oral, they may be administered parenterally as well. Such parenteral administration may be the preferred mode of administration for the treatment of certain collagenase-mediated disorders or diseases.
For purposes of parenteral administration, solutions of tenidap or a salt thereof in sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solutions of the corresponding water soluble base salts previously enumerated. Such aqueous solutions should be suitably buffered if necessary, and the liquid diluent rendered isotopic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular and subcutaneous injection purposes.’ In this connection, the sterile aqueous media employed are readily obtained by standard techniques well known to those skilled in the art. For instance, distilled water is ordinarily used as the liquid diluent and the final preparation is passed through a suitable bacterial filter such as a sintered glass filter or a diatomaceous-earth or unglazed porcelain filter. Preferred filters of this type include the Berkefeld, the Chamberland and the Asbestos Disk-Metal Seitz filter, wherein the fluid is sucked into a sterile container with the aid of a sudtion pump. The necessary steps should be taken throughout the preparation of these injectable solutions to insure that the final products are obtained in a sterile condition. For purposes of transdermal administration, the dosage form of the particular compound may include, by way of example, solutions, lotions, ointments, creams, gels, suppositories, rate-limiting sustained release formulations and devices therefor. Such dosage forms comprise the particular compound and may include ethanol, water, penetration enhancer and inert carriers such as gel-producing materials, mineral oil, emulsifying agents, benzyl alcohol and the like.
Specific transdermal flux enhancing compositions are disclosed in European Patent Application 271,983 and European Patent Application 331,382, which have been filed in the name of the assignee of this a .invention, the teachings of which are incorporated herein by reference. For purposes of topical 15 administration, the dosage form of the particular compound may include, by way of example and not of limitation, solutions, lotions, ointments, creams and gels.
The’ability of tenidap to inhibit the activation of !ollagenase and to inhibit the activity of myeloperoqidase were determined by the procedures described Lelow.
l Whole human blood from normal volunteers was obtained by venipuncture into heparinized syringes.
‘inI The majority of the red cells were removed by dextran sedimentation and neutrophils.were separated by density centrifugation over hypaque ficoll. The neutrophil rich fraction was washed and residual red cells were removed by hypotonic lysis according to the procedure described by Blackburn, W.D. et al., Arthritis Rheum.
30:1006-1014 (1987). The neutrophils so prepared were used in the assays described below and cell viability was assured by determining their ability to exclude -11typan blue. In each assay the cell viability routinely exceeded To assay for inhibition of release of activated collagenase by neutrophils, the following assay was performed. Neutrophil cell suspensions were incubated at 370C for 15-30 minutes in the presence of varying concentrations of tenidap or other compound under study. Tenidap was dissolved and diluted in water and added to the cells directly therefrom. Other compounds tested were initially dissolved in 0.1M NaOH and then diluted in water prior to addition to the cells. After the cells had been incubated in the presence of tenidap or other compound under study, the cell suspensions (5 x 10 6 cells/ml, 125 pl/well) were added to IgG coated and bovine serum albumin (BSA) blocked wells of microtiter plates and incubated for 45 minutes at 37 0
C.
As controls, similar incubations were performed in.the.
absence of IgG. Following incubation, the cell suspensions were centrifuged (750 x g) for 5 minutes at 4°C. The supernatants were removed and DFP (diiscpropylfluorophosphate) was added to a final -3 concentration of 10-3M to inactivate serine proteases.
Then, the collagenase activity in the DFP treated supernatants was determined by incubating, in triplicate, 200 ul aliquots of supernatant with 3 H-labeled reconstituted type-I collagen fibrils in 7 mm flat bottom tissue culture wells (Linbroe, Cat #76-032-05, Flow Laboratories McLean, Va) as described by Johnson-Wint, Anal. Biochem. 104:175-181 (1980).
The reconstituted fibrils in each well contained 75 jg of a mixture of 3H-labeled and unlabeled collagen with -12an activity of 7,000 cpm. To determine the total radioactivity potentially released from the fibrils in each experiment, the reconstituted fibrils were also S incubated with a mixture of clostridial collagenase (250 mg/ml HBSS (Hank’s balanced salt solution, GIBCO, Grand Island, New York)). To maximize sensitivity and specificity of the assay, incubations were performed for eighteen hours in triplicate at 37 0 C. At the end of the incubation period, the supernatants were aspirated from each well and the radioactivity was determined by counting in a liquid scintillation counter. Greater than 99% of the radioactivity applied to each well was recovered from wells incubated with bacterial collagenase. Average counts per minute released by fibrils incubated with buffer (HBSS) alone were subtracted from the cpm measured in each supernatant. The resulting triplicate values for.each supernatant were averaged and divided by the average cpm released by the bacterial collagenase to determine the percent fibril lysis produced by each supernatant.
The total activated collagen released during the eighteen hour incubation was then calculated and divided by the incubation time to yield values for the collagenase activity (ng collagen degraded/min) in each supernatant.
In parallel experiments, release of total collagenase into the supernatants was determined by activating latent collagenase in the supernatants with 1.0 mM mersalyl (Harris, E.D. and Vater, C.A., Methodology of collagenase research: substrate purification, enzyme activation and purification.
Collagenase in Normal Pathological Connective Tissues.
-13- Edited by D.E. Woolley, J.M. Evanson, Chichester, John Wiley Sons, 1980) prior to addition of the supernatants to the radiolabeled collagen fibrils. To avoid underestimation of total collagenase released due to inhibition of protease activity by oxidative metabolites generated during neutrophil activation, the supernatants used for these determinations were derived from neutrophils activated in the presence of 1.0 mM O1 sodium azide (an inhibitor of myeloperoxidase).
Incubations and calculations of collagenase activity in the mersalyl treated supernatants were performed as described above.
Employing the foregoing assay with tenidap, 15 piroxicam, indomethacin, ibuprofen naproxen, at peak drug concentrations, yielded the data shown in I Table I, below.
TABLE
I
Inhibition of Activated Neutrophil 20 Collagenase Release Peak i Compound Concentration (uM) Inhibition titl Tenidap 87.5 64 Piroxicam 25 18 Indomethacin 2.5 14 Ibuprofen 175 0 Naproxen 80 0 As shown in Table I, ibuprofen and naproxen, both cyclooxygenase inhibitors had no inhibitory effect on -14the release of activated collagenase by neutrophils.
Piroxicam and indomethacin, both also cyclooxygenase inhibitors, had some inhibitory effect on the release of activated collagenase, but at supraphysiological concentrations for those compounds. Tenidap, at clinically relevant concentrations, significantly inhibited the release of activated collagenase from neutrophils.
A further assay was conducted wherein neutrophils, prepared as described above, were incubated in the presence and in the absence of tenidap and then stimulated by incubation in the presence of IgG, all as described above. The supernatants were then activated by the addition of organic mercurial mersasyl. As a result of this assay, it was found that tenidap inhibited by 22% the total amount of collagenase released by neutrophils. Thus, it was concluded that tenidap inhibition of the release of activated collagenase is due to inhibition of the activation of collagenase.
The ability of tenidap to inhibit the activity of myeloperoxidase was demonstrated by the following assay. Neutrophils (1.25 x 106/ml, prepared as described above) were incubated for 60 minutes at 37 0
C
in either BSA or IgG coated tissue culture wells which had been blocked with BSA. Following incubation, the wells were aspirated and the cells were removed by centrifugation. Separately, myeloperoxidase was extracted from whole neutrophils with 1M NaCl and separated from cell debris by centrifugation. The supernatants were dialyzed against HBSS. Then, to the dialyzed supernatants were added varying concentrations of tenidap. Myeloperoxidase activity was then determined by adding 20 pi of the supernatant to 300 pl S of 0.2M sodium acetate buffer, pH 4.5, containing 17 mg of 2,2’-azino-di-(3-ethylbenzthiazoline)sulfonic acid and 600 p1 of 0.003% hydrogen peroxide. The activity of myeloperoxidase in the supernatant was then determined by the change in absorbance at 412 nm using IO a spectrophotometer as described by Shindler, J.S.
et al., Eur. J. Biochem. 65:325-331 (1976).

Claims (3)

1. A method of inhibiting the activity of myeloperoxidase in a mammal in need thereof which comprises administering to said mammal a myeloperoxidase inhibiting amount of tenidap or a pharmaceutically- acceptable base salt thereof.

2. The method according to claim 1 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered orally.

3. The method according to claim 1 or claim 2 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered parenterally. DATED this EIGHTH day of JULY 1992 Pfizer Inc. Patent Attorneys for the Applicant SPRUSON FERGUSON RXJ/0930Z USE OF TENIDAP TO INHIBIT THE ACTIVITY OF MYELOPEROXIDASE Abstract This invention relates to the use of tenidap, 5-chloro-2,3-dihydro- 2-oxo-3-(2-tlienylcarbonyl)-lnidole-l-carboxamide, and the pharmaceutically-acceptable base salts thereof to inhibit the activity of myelIope rox ida se i n a mammal1. This invention also relates to the use of tenidap and its salts for treating diseases such as bone resorption disorders, corneal ulceration, periodontal disease, inflammatory disease and wounds of the skin and burns in mammals. the methods of this invention comprise administering an effective amount of tenidap or salts thereof to a mamimal. foot to* RXJ/0930Z

AU19574/92A
1990-03-19
1992-07-09
Use of tenidap to inhibit the activity of myeloperoxidase

Ceased

AU637745B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US495868

1983-05-18

US07/495,868

US5008283A
(en)

1990-03-19
1990-03-19
Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase

Related Parent Applications (1)

Application Number
Title
Priority Date
Filing Date

AU73587/91A
Division

AU625409B2
(en)

1990-03-19
1991-03-18
Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase

Publications (2)

Publication Number
Publication Date

AU1957492A

AU1957492A
(en)

1992-09-10

AU637745B2
true

AU637745B2
(en)

1993-06-03

Family
ID=23970312
Family Applications (2)

Application Number
Title
Priority Date
Filing Date

AU73587/91A
Ceased

AU625409B2
(en)

1990-03-19
1991-03-18
Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase

AU19574/92A
Ceased

AU637745B2
(en)

1990-03-19
1992-07-09
Use of tenidap to inhibit the activity of myeloperoxidase

Family Applications Before (1)

Application Number
Title
Priority Date
Filing Date

AU73587/91A
Ceased

AU625409B2
(en)

1990-03-19
1991-03-18
Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase

Country Status (14)

Country
Link

US
(1)

US5008283A
(en)

EP
(1)

EP0448253A3
(en)

JP
(1)

JPH04234815A
(en)

KR
(1)

KR930010581B1
(en)

AU
(2)

AU625409B2
(en)

CA
(1)

CA2038409C
(en)

HU
(1)

HUT60623A
(en)

IE
(1)

IE910860A1
(en)

IL
(1)

IL97521A
(en)

MY
(1)

MY107235A
(en)

NZ
(1)

NZ237451A
(en)

PT
(1)

PT97061B
(en)

SG
(1)

SG48397A1
(en)

ZA
(1)

ZA911979B
(en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5122534A
(en)

1991-02-08
1992-06-16
Pfizer Inc.
Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides

TW438798B
(en)

1992-10-07
2001-06-07
Pfizer
3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions

US5298522A
(en)

1993-01-22
1994-03-29
Pfizer Inc.
6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio

ES2076106B1
(en)

1993-08-26
1996-06-16
Pfizer

PHARMACEUTICAL COMPOSITIONS BASED ON 2-OXINDOL-1-CARBOXAMIDES 3-SUBSTITUTED

US5795902A
(en)

1993-09-02
1998-08-18
Pfizer Inc.
3-substituted 2-oxindole-1 carboxamide pharmaceutical compositions

US5516699A
(en)

1994-02-16
1996-05-14
Institute Of Molecular Biology, Inc.
Pyridinoline crosslinks as markers of periodontal and peri-implant disease activity

US5545656A
(en)

1995-04-05
1996-08-13
Pfizer Inc.
2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer’s disease

US5827840A
(en)

1996-08-01
1998-10-27
The Research Foundation Of State University Of New York
Promotion of wound healing by chemically-modified tetracyclines

WO1999059561A2
(en)

1998-05-18
1999-11-25
Hensley, Kenneth, L.
Resveratrol inhibition of myeloperoxidase

US6544556B1
(en)

2000-09-11
2003-04-08
Andrx Corporation
Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor

PT2026651E
(en)

2006-03-08
2013-06-04
Cortria Corp
Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries

Family Cites Families (8)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4556672A
(en)

1984-03-19
1985-12-03
Pfizer Inc.
3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents

US4678802A
(en)

1985-07-09
1987-07-07
Pfizer Inc.
1-acylcarbamoyloxindole-3-carboxamides as antiinflammatory agents

UA25898A1
(en)

1987-02-02
1999-02-26
Пфайзер Інк.

METHOD OF OBTAINING CRYSTAL HATRIUM SALT 5-CHLORINE-3- (2-TECHOYL) -2-OXYHIDOL-1-CARBOXAMIDE

EP0287196B1
(en)

1987-02-18
1994-11-23
Beecham Group Plc
Indole derivatives, process for their preparation and pharmaceutical compositions containing them

US4861794A
(en)

1988-04-13
1989-08-29
Pfizer Inc.
3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis

US4853409A
(en)

1988-04-13
1989-08-01
Pfizer Inc.
3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function

DE3814504A1
(en)

1988-04-29
1989-11-09
Bayer Ag

(ALPHA) -SUBSTITUTED 4- (CHINOLIN-2-YL-METHOXY) PHENYL ACETIC ACIDS AND SITES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICAMENTS

US5006547A
(en)

1990-03-19
1991-04-09
Pfizer Inc.
Tenidap as an inhibitor of the release of elastase by neutrophils

1990

1990-03-19
US
US07/495,868
patent/US5008283A/en
not_active
Expired – Lifetime

1991

1991-03-07
SG
SG1996009351A
patent/SG48397A1/en
unknown

1991-03-07
EP
EP19910301890
patent/EP0448253A3/en
not_active
Withdrawn

1991-03-12
IL
IL9752191A
patent/IL97521A/en
not_active
IP Right Cessation

1991-03-15
NZ
NZ237451A
patent/NZ237451A/en
unknown

1991-03-15
CA
CA002038409A
patent/CA2038409C/en
not_active
Expired – Fee Related

1991-03-15
IE
IE086091A
patent/IE910860A1/en
unknown

1991-03-18
ZA
ZA911979A
patent/ZA911979B/en
unknown

1991-03-18
HU
HU91872A
patent/HUT60623A/en
unknown

1991-03-18
KR
KR1019910004236A
patent/KR930010581B1/en
not_active
IP Right Cessation

1991-03-18
PT
PT97061A
patent/PT97061B/en
not_active
IP Right Cessation

1991-03-18
AU
AU73587/91A
patent/AU625409B2/en
not_active
Ceased

1991-03-18
MY
MYPI91000438A
patent/MY107235A/en
unknown

1991-03-19
JP
JP3130750A
patent/JPH04234815A/en
active
Pending

1992

1992-07-09
AU
AU19574/92A
patent/AU637745B2/en
not_active
Ceased

Also Published As

Publication number
Publication date

EP0448253A3
(en)

1992-04-01

IL97521A0
(en)

1992-06-21

AU625409B2
(en)

1992-07-09

SG48397A1
(en)

1998-04-17

PT97061B
(en)

1998-07-31

US5008283A
(en)

1991-04-16

HUT60623A
(en)

1992-10-28

CA2038409C
(en)

1995-01-24

IL97521A
(en)

1995-12-31

HU910872D0
(en)

1991-09-30

AU7358791A
(en)

1991-12-12

NZ237451A
(en)

1997-02-24

EP0448253A2
(en)

1991-09-25

KR930010581B1
(en)

1993-10-30

MY107235A
(en)

1995-10-31

AU1957492A
(en)

1992-09-10

IE910860A1
(en)

1991-09-25

PT97061A
(en)

1991-10-31

JPH04234815A
(en)

1992-08-24

KR910016326A
(en)

1991-11-05

ZA911979B
(en)

1992-10-28

Contact information